These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

979 related articles for article (PubMed ID: 23461426)

  • 1. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
    Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
    J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic Jordanians: a Markov modeling of cardiovascular diseases prevention.
    Mousa R; Hammad E
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1069-1079. PubMed ID: 33213221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Pharmacoeconomic Model to Demonstrate the Effect of Clinical Pharmacist Involvement in Diabetes Management.
    Ourth H; Nelson J; Spoutz P; Morreale AP
    J Manag Care Spec Pharm; 2018 May; 24(5):449-457. PubMed ID: 29694293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an outpatient pharmacy clinical services program on adherence and clinical outcomes among patients with diabetes and/or coronary artery disease.
    Spence MM; Makarem AF; Reyes SL; Rosa LL; Nguyen C; Oyekan EA; Kiyohara AT
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1036-45. PubMed ID: 25278326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.
    Asche CV; Hippler SE; Eurich DT
    Pharmacoeconomics; 2014 Jan; 32(1):15-27. PubMed ID: 24357160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 8. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan.
    Jarab AS; Alqudah SG; Mukattash TL; Shattat G; Al-Qirim T
    J Manag Care Pharm; 2012 Sep; 18(7):516-26. PubMed ID: 22971205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes.
    McAdam-Marx C; Dahal A; Jennings B; Singhal M; Gunning K
    J Manag Care Spec Pharm; 2015 Jun; 21(6):452-68. PubMed ID: 26011547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of medication therapy management services for patients with cardiovascular disease in a self-insured employer health plan.
    Wittayanukorn S; Westrick SC; Hansen RA; Billor N; Braxton-Lloyd K; Fox BI; Garza KB
    J Manag Care Pharm; 2013 Jun; 19(5):385-95. PubMed ID: 23697476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes.
    Mukherjee J; Sternhufvud C; Smith N; Bell K; Stott-Miller M; McMorrow D; Johnston S
    J Manag Care Spec Pharm; 2016 May; 22(5):449-66. PubMed ID: 27123909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial.
    Wu WC; Taveira TH; Jeffery S; Jiang L; Tokuda L; Musial J; Cohen LB; Uhrle F
    PLoS One; 2018; 13(4):e0195898. PubMed ID: 29672567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials.
    Pousinho S; Morgado M; Falcão A; Alves G
    J Manag Care Spec Pharm; 2016 May; 22(5):493-515. PubMed ID: 27123912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
    Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
    J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
    Annemans L; Marbaix S; Webb K; Van Gaal L; Scheen A
    Clin Drug Investig; 2010; 30(2):133-42. PubMed ID: 20067331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.